Julie Allickson: How early automation strategies reduce costs and improve patient access
About this episode
Dr. Julie Allickson discusses the impact of automation and AI on reducing costs and improving patient access in regenerative medicine.
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Dr. Julie Allickson, Chief Technology Officer for Mayo Clinic's Center for Regenerative Biotherapeutics. With over 30 years pioneering regenerative medicine - from early bone marrow transplant programs to today's cutting-edge cell and gene therapies - Julie shares her journey and insights on translating innovative therapies from discovery to clinical impact. Together, they explore how academic medical centers are evolving to bridge the gap between research and commercialization through integrated manufacturing capabilities, multi-site clinical trials, and strategic partnerships. Julie discusses Mayo Clinic's approach to managing 30+ clinical trials across three sites, the critical role of automation and AI in reducing costs and improving scalability, and why thinking about commercial viability early in development is essential widespread patient access. Learn more: https://www.linkedin.com/in/julie-g-allickson-phd-76129062/
More episodes of Ori Spotlight
- Ken Harris: Why AI and automation are CGT’s next inflection point
- Joe DePinto: Why advanced therapies need a new delivery model
- Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy
- John Khoury: The CGT developers who adapt new manufacturing techniques early will lead later
- Warner Biddle: Building a commercial model for CAR-T in autoimmune care
- Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success
Explore listener stats, chart rankings, contacts and more on the Ori Spotlight podcast page.